Evotec OAI of Germany says that, during the first nine months of 2001,revenues amounted to 39.6 million euros ($35.6 million), an increase of 304% over the same period last year, and the firm is expecting further growth in the fourth quarter, which is usually the strongest for "revenue recognition in our fiscal year."
Excluding non-cash effects, the firm's operating loss decreased almost 11% to 11.9 million euros, although including these factors (which mainly reflect goodwill amortization from acquisitions), the operating loss was 114.9 million euros. However, this type of charge will no longer be accounted for from January 1, 2002, and beyond, Evotec noted, adding that, excluding these non-cash effects, the net loss was 11.8 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze